LY4100511 (DC-853)

LY4100511 · DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company

Drug timelines are a Plus or Pro feature.

6 regulatory and trial events tracked for LY4100511 (DC-853), covering 2025-01-24 to 2026-08-18. Get the full timeline:

Most recent: Clinical Trial Results: A Study of LY4100511 (DC-853) in Adult Participants With Moderate-to-Severe Plaque Psoriasis [Phase 2]